The Daily

Huawei’s next-gen AI accelerator, the 950PR, is finally getting serious traction with China’s biggest private-sector buyers — Reuters reports that customer testing has gone well and firms including ByteDance and Alibaba plan to place orders. Two details matter: compatibility and volume. Sources say the 950PR is more compatible with Nvidia’s CUDA ecosystem (easier model migration than Huawei’s CANN path) and tuned for inference workloads, even if raw compute only improves slightly over the Ascend 910C. Huawei reportedly plans to ship around 750,000 950PR chips this year, with mass production expected to begin next month and broader shipments in H2 2026. Pricing is cited at roughly 50,000 yuan per card (DDR) and 70,000 yuan for an HBM variant — the clearest signal yet that China’s AI stack is hardening under export controls.

Bloomberg Law reports a split decision from the US Court of Appeals for the Third Circuit: a Pennsylvania attorney was reprimanded after filing briefs packed with AI-generated citations that were simply wrong. The court said he failed to provide competent representation because he “neither read nor verified the existence of the cited authorities.” The lesson isn’t “don’t use AI” — it’s that courts are now treating verification as a baseline professional duty, not an optional best practice. Expect this to ripple into firm policy: AI usage logs, cite-check workflows, and maybe explicit sign-off steps before filing.

TechCrunch’s investor debrief from Y Combinator’s Winter 2026 Demo Day reads like a market snapshot: in a world where the accelerator now runs four cohorts a year, the “default” startup valuation this quarter is said to be around $30M. At the top end, TechCrunch hears that a couple of companies raised at about $100M — but only with $1M+ run-rate revenue already on the books. The standouts are delightfully varied: Hex pitching AI agents as always-on pen-testers; GrazeMate using autonomous drones to herd cattle; and GRU claiming a “moon factory” to turn lunar soil into bricks, with a lunar hotel target of 2032.

The Lakers handled the Nets 116–99, extending their home streak to an 8th straight win. The bigger picture is standings pressure: the win moved Los Angeles to 48–26 on the season, right where seeding becomes less about vibes and more about avoiding the wrong first-round matchup. Brooklyn, meanwhile, looked like a team still searching for late-season identity — the kind of loss that feels less like a single game and more like a warning light.

Denver erased a 14-point deficit to beat Utah 135–129 — the kind of late-March win that tests whether a contender can flip intensity on demand. The Nuggets improved to 47–28, which matters because the West is tight enough that one comeback now can save you a road series later. Utah’s defense had stretches of real resistance, but not enough stops when the game shifted into “possession economy” mode.

Yahoo Sports (via The Big Lead) says the league is actively workshopping three anti-tanking proposals after recent fines (Utah: $500,000; Indiana: $100,000), with changes potentially targeted at the 2027 draft. The concepts vary, but the common goal is to flatten incentives: one option is an 18-team lottery that pulls in seeds 7–15 from both conferences and gives the bottom 10 teams equal 8% odds at the top pick. Another is a 22-team lottery based on two-year records (even including some early playoff exits) with a suggested minimum win threshold (example given: 25 wins). The details will change — but the message is clear: the league wants “lose less, compete more” without breaking the draft.

The Art Newspaper reports that at least 34 Members of the European Parliament signed a letter calling for suspension of all EU funding to the Venice Biennale if Russia’s participation proceeds. The letter (published by Politico) shows 34 signatories, and Politico says 37 MEPs have signed. The political lever is money: the EU grant has been reported as about €2m. If you’re traveling for the Biennale, this matters because the pavilion story is no longer an art-world footnote — it’s becoming a test of how cultural institutions handle sanctions-era geopolitics in public.

CNN’s travel round-up points to TIME’s list of the 100 “greatest places of 2026,” with a few hard, tempting anchors. China’s Huajiang Grand Canyon Bridge rises about 2,050 feet above the Beipan River and cuts a canyon crossing from two hours to two minutes. Egypt’s Grand Egyptian Museum in Giza opened in November 2025, after a budget that ballooned to $1B+, and is billed as the largest museum dedicated to a single civilization. Lists are fluffy — but the numbers here are not, and they’re strong travel planning signals.

Novo Nordisk says the FDA approved Awiqli (insulin icodec-abae) on March 26, 2026 — positioned as the first and only once-weekly, long-acting basal insulin for adults with type 2 diabetes, at 700 units/mL. The pitch is adherence math: cutting basal injections from seven to one per week for patients who struggle with daily routines. The approval is backed by the ONWARDS phase 3a program: four randomized, active-controlled, treat-to-target trials in roughly 2,680 adults with uncontrolled T2D, comparing once-weekly icodec to daily basal insulin and showing A1C reduction. The key implementation question now is real-world titration and safety monitoring — weekly dosing changes the cadence of both.

EMA’s CHMP published its March meeting highlights and recommended five medicines for approval: Adstiladrin (conditional; BCG-unresponsive NMIBC), Imdylltra (tarlatamab; relapsed extensive-stage SCLC), Joenja (leniolisib; APDS, estimated 1–2 per million incidence worldwide), Zepzelca (lurbinectedin; maintenance in extensive-stage SCLC), and Bopediat (furosemide; paediatric-use marketing authorisation). Two signals stand out for practice: a new reflection paper on a tailored clinical approach in biosimilar development (less clinical data for some biosimilars), and a referral conclusion recommending Tecovirimat SIGA should no longer be used for mpox.

Fierce Biotech covers Nature Medicine data on EsoBiotec’s in vivo BCMA CAR-T candidate ESO‑T01 in a small Chinese phase 1 study in multiple myeloma. In five treated patients, four achieved objective responses and three reached stringent complete remission by day 60. The safety profile is the stress test: all patients had grade ≥3 adverse events; CRS occurred in four (grade 3 in three), and one patient died 19 days after dosing due to spinal cord compression linked to a lesion. The takeaway is less hype and more calibration: in vivo CAR-T may shift manufacturing friction, but it doesn’t magically erase CAR-T-class toxicities.

Stage 1 results from the randomized phase 3 PRESERVE‑003 trial report a surprisingly strong overall-survival signal for gotistobart (BNT316/ONC‑392), a pH‑sensitive anti‑CTLA‑4 antibody designed to selectively deplete regulatory T cells in the tumor microenvironment. Patients with metastatic squamous NSCLC were randomized to gotistobart (N=45) or docetaxel (N=42), and after a median follow-up of 14.5 months, median OS was not reached with gotistobart vs 10.0 months with docetaxel (HR 0.46; nominal P=0.0102). Grade ≥3 treatment-related AEs were 42% vs 49%, respectively. This doesn’t settle CTLA-4’s long-running toxicity/benefit debate — but it suggests there’s still room for smarter antibody engineering in checkpoint land.

A PubMed-indexed report highlights an under-discussed complication in the era of T-cell redirection: hepatitis E virus (HEV) infections in multiple myeloma patients. The authors describe 7 MM patients diagnosed within less than one year, all confirmed by HEV RNA PCR in blood. Even without fulminant hepatitis, HEV forced meaningful therapy disruption: autologous stem cell transplant was postponed, CAR‑T lymphocyte apheresis delayed, and bispecific regimens suspended for up to five months. Ribavirin was started in 4 cases, but 3 patients on T‑cell‑redirecting therapies progressed to chronic infection despite treatment — and one patient had HEV RNA detected in cerebrospinal fluid with persistent vertigo, suggesting neuroinvasion.

Kurzliste: 15.–21.4., Theater Odeon · 50+ Veranstaltungen · Ausstellung mit 1.000+ Kinder- & Jugendbüchern · freier Eintritt · Anmeldung erforderlich. WIENXTRA kündigt eine ganze Woche Programm rund ums Lesen, Erzählen und Illustrieren an — mit Lesungen, Workshops, Erzähltheater und Kreativformaten. Vormittags ist viel auf Schulklassen ausgerichtet; nachmittags gibt es Slots, die auch für Hort/Ganztag gut passen. Wer im April eine „fixe“ Kulturaktivität für Kinder sucht, bekommt hier ein sehr dichtes, niedrigschwelliges Angebot.

Kurzliste: Ostermarkt Schönbrunn · Altwiener Ostermarkt Freyung · Kindermuseum Schloss Schönbrunn (21.3.–6.4.) · Playworld (Indoor) · Familien-Programme in Museen. Mamilade sammelt Ideen, warum Wien rund um Ostern als Familien-Trip besonders gut funktioniert: viel Rahmenprogramm, Märkte als „kostenloser Spaziergang mit Inhalt“ und etliche Indoor-Optionen, falls das Wetter kippt. Für Planung zählt vor allem der Zeitraum: das Kindermuseum-Programm wird mit 21. März bis 6. April angegeben — also jetzt schon relevant. Gute Reminder-Seite, wenn du mehrere Optionen nebeneinander brauchst.

Falter.morgen beschreibt die Pläne für den Ring-Radweg als „Entflechtung“: Radverkehr soll (wo möglich) auf die Nebenfahrbahn verlegt werden, Fußgänger bekommen die Alleen. Konkret wird es beim Abschnitt Schottenring–Schottentor: Baustart Herbst 2026, Fertigstellung Mitte 2027, mit einem baulich getrennten Radweg von 4,50 Metern Breite. Dazu: 50 zusätzliche Sitzmöglichkeiten, 900 m² Grün-/Beetflächen und 12 neue Bäume. Der Preis bleibt noch vage („einstelliger Millionenbetrag“) — aber die Flächenaufteilung ist die eigentliche politische Aussage.

Kurzliste: Addicted to Rock (1060) · B72 (1080) · Chelsea (1080) · Porgy & Bess (1010) · Needle Vinyl Bar (1010). Goodnight.at hat eine angenehm konkrete Sammlung von Locations, die nicht „nur Bar“ sind, sondern wirklich mit Programm (oder zumindest Musik-Konzept). Praktisch ist die Mischung: Gürtel-Klassiker (B72, Chelsea) neben Innenstadt-Optionen (Needle, Porgy). Wenn du Besuch hast und einen Abend brauchst, der ohne Club-Ticket funktioniert, ist das ein brauchbarer Startpunkt.